{{Rsnum
|rsid=750124
|Gene=FAM38A
|Chromosome=16
|position=88746706
|Orientation=plus
|GMAF=0.4729
|Gene_s=PIEZO1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 36.3 | 49.6 | 14.2
| HCB | 13.1 | 50.4 | 36.5
| JPT | 17.7 | 54.0 | 28.3
| YRI | 4.8 | 40.1 | 55.1
| ASW | 14.0 | 47.4 | 38.6
| CHB | 13.1 | 50.4 | 36.5
| CHD | 12.0 | 47.2 | 40.7
| GIH | 45.5 | 42.6 | 11.9
| LWK | 15.5 | 51.8 | 32.7
| MEX | 22.4 | 60.3 | 17.2
| MKK | 18.6 | 45.5 | 35.9
| TSI | 32.4 | 54.9 | 12.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs750124
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109384
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs750124
|overall_frequency_n=57
|overall_frequency_d=124
|overall_frequency=0.459677
|n_genomes=31
|n_genomes_annotated=0
|n_haplomes=45
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}